New study supports statin’s anti-dementia effects

NEW YORK (Reuters Health) - In the largest cohort study to date, treatment with a cholesterol-lowering statin drug was found to reduce new cases of Alzheimer’s disease, regardless of the specific type of statin used or a person’s genetic risk for the disease.

Numerous studies have looked at the relationship between statin use and the development of Alzheimer’s disease, with conflicting results. One explanation for the inconsistencies is that only the fat soluble or “lipophilic” statins, which could get into the brain more easily than water soluble or “hydrophilic” statins, were included in the studies.

To explore these issues, Dr. M. M. B. Breteler and colleagues at the Erasmus Medical Center in Rotterdam, the Netherlands, analyzed data from the prospective, population-based Rotterdam Study. The analysis included 6992 subjects, 55 years old or older, who were free of dementia when examined between 1990 and 1993.

During follow-up until 2005 (an average of 9.2 years), 582 subjects were diagnosed with Alzheimer’s. After controlling for social, demographic and clinical factors that might raise a person’s risk of getting the disease, statin users had a significant 43 percent reduced risk of Alzheimer’s disease compared with those who never used statins.

The protective effect was similar for fat soluble and water soluble statins. Examples of fat soluble statins are atorvastatin (Lipitor), simvastatin (Zocor), lovastatin (Mevacor), or fluvastatin (Lescol). An example of a water soluble statin is pravastatin (Pravachol).

The protective effect of statin use against Alzheimer’s disease was also similar for persons with and without the major gene mutation associated with an increased risk of Alzheimer’s disease (i.e., the apolipoprotein E-epsilon-4 allele).

On the other hand, the use of other cholesterol-lowering drugs such as fibrates or nicotinic acid failed to exhibit similar benefit, Breteler’s team reports.

The findings appear in this month’s issue of the Journal of Neurology, Neurosurgery and Psychiatry.

In a commentary published with the study, Dr. Larry Sparks at the Sun Health Research Institute in Sun City, Arizona, states: “All in all, it is clear that somewhere between normal cognitive performance and profound dementia of Alzheimer’s disease, statin therapy exerts a beneficial effect.”

He points out that nearly 20 previous studies have assessed the effect of statin use on later risk of Alzheimer’s disease in older people, and the majority found substantial benefit.

Sparks concludes that “it is our task to identify at what point in time statin therapy might be of the greatest benefit in order to effectively target which patients to treat with cholesterol-lowering statins.”

SOURCE: Journal of Neurology, Neurosurgery and Psychiatry, January 2009.


Related Posts:

By Michelle Rizzo NEW YORK (Reuters Health) - Treatment with a cholesterol-lowering “statin” drug may very occasionally cause double-vision, eyelid-droop, or weakness of the muscles that control eye movement, investigators report.. Dr. F. W. Fraunfelder and Dr. Amanda B. Richards, from the Casey Eye Institute, Oregon Health & Science University, Portland, investigated adverse events of this type

Full Post: Statins may cause rare instances of eye disorders

By Will Dunham WASHINGTON (Reuters) - Nearly 20 percent more U.S. men over 50 and women over 60 stand to benefit from taking statins, based on the findings of a recent study on the cholesterol-lowering drugs, U.S. researchers said on Tuesday. Their research stakes out a potentially expanded market for statins, already the world’s top-selling drugs. The so-called

Full Post: Statins may help millions more people: study

By Bill Berkrot and Ransdell Pierson NEW ORLEANS (Reuters) - AstraZeneca’s cholesterol fighter Crestor dramatically cut deaths, heart attacks and strokes in patients with healthy cholesterol levels but who had high levels of a protein associated with heart disease, researchers said on Sunday. Crestor, known chemically as rosuvastatin, reduced heart attack, stroke, need for bypass or angioplasty

Full Post: AstraZeneca’s Crestor cuts deaths and heart attacks

NEW YORK (Reuters Health) - Low levels of cystatin C — a blood protein commonly used as a measure of kidney function — may be a risk factor for the development of Alzheimer’s disease in elderly men, researchers report. Cystatin C is produced by nearly all human cells and available in all body fluids. During the

Full Post: Blood protein tied to Alzheimer’s disease risk

By Will Dunham WASHINGTON (Reuters) - High doses of B vitamins failed to slow cognitive decline in people with Alzheimer’s disease, dashing the hopes for a new weapon against the fatal, mind-robbing ailment, U.S. researchers said on Tuesday. Experts had viewed B vitamins as a potential way to lower the risk of Alzheimer’s disease or slow its

Full Post: B vitamins fail in U.S. Alzheimer’s disease study

Site Navigation

Most Read